Technology News and Headlines

STAT+: Ocular’s Experimental Eye Drug Beats Low Dose of Regeneron’s Eylea in Late-Stage Trial

Ocular Therapeutix announced that its experimental drug Axpaxli met the primary endpoint in a Phase 3 trial for wet age‑related macular degeneration, maintaining vision in 74% of patients at nine months and 66% at one year after a single injection. By comparison, a low‑dose regimen of Regeneron’s Eylea preserved vision in 56% and 44% of patients at the same intervals. The results show a statistically significant benefit but the efficacy gap was narrower than investors anticipated, prompting questions about Axpaxli’s commercial upside in a crowded market. The study highlights the possibility of less frequent dosing for a disease that typically requires monthly injections.